Westlake Plans Proxy Fight as Axiall Rejects New Bid

North American vinyl building products company Axiall has unanimously rejected a second bid from rival Westlake Chemical, this time worth $3.1 billion. Westlake has subsequently responded by formally ending negotiations and asking Axiall’s shareholders to elect a new board.

The revised bid, submitted on Mar. 29, offered $23.12 per Axiall share. This was an increase on the $20 per share offered in January this year, which valued Axiall at $2.9 billion.

In a written response, Axiall CEO, Timothy Mann described the offer as “inadequate”. He said the value proposed by Westlake ignores the high quality of Axiall’s assets, its significant growth potential and the powerful synergies available in a combination, adding that the new bid is inconsistent with the board’s understanding from a meeting held in Houston on Mar. 8.

Mann said he believes the synergies from a merger could be as high as $270 million annually, some $210 million more than the $60 million in synergies outlined in Westlake’s proposal.

In his letter to Axiall shareholders, Westlake CEO Albert Chao said the company would now file preliminary proxy materials with the US Securities and Exchange Commission (SEC) to elect 10 new candidates for the rival’s board, who would be “willing to evaluate all options in accordance with their fiduciary duties.”

Chao said Axiall’s board had refused to make a counterproposal or otherwise negotiate or provide any constructive feedback. He added that the company had consistently overestimated its earnings power and had a track record of failing to deliver on its operational and strategic objectives.

Axiall, formerly known as Georgia Gulf, has been under pressure in recent weeks from its biggest investor, Shapiro Capital Management, to negotiate with Westlake.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

Whitepaper

Cannabis Extraction — Temperature Control Systems in Action

Cannabis Extraction — Temperature Control Systems in Action

Cannabis is a crop that has been cultivated for thousands of years and contains many pharmacologically active substances.

most read

Photo
24.01.2025 • News

CEFIC Publishes 2024 Facts and Figures Report

CEFIC , the European Chemical Industry Council, has published its 2024 Facts & Figures report, which reinforces the need to take bold and urgent action to secure Europe’s industrial future, not only to implement the Green Deal but also to prevent further de-industrialization in Europe.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.